{"gene":"GOLM1","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2000,"finding":"GP73/GOLM1 is an integral membrane protein localized to the Golgi apparatus, as determined by in vitro transcription-translation studies and immunolocalization experiments using epitope-tagged GP73; it is preferentially expressed by epithelial cells and is normally absent from hepatocytes but upregulated in response to viral infection.","method":"In vitro transcription-translation, epitope-tag immunolocalization, Northern blot, immunohistochemistry","journal":"Gene","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (in vitro translation, epitope-tag localization, IHC) in the foundational characterization paper, replicated in subsequent studies","pmids":["10831838"],"is_preprint":false},{"year":2002,"finding":"GP73 expression is upregulated at the RNA and protein level by adenovirus infection, and this induction requires the CtBP interaction domain (CID) of the adenoviral E1A protein, as demonstrated by infection with a panel of E1A mutant adenoviruses and transient transfection of wild-type vs. mutant E1A constructs.","method":"RNase protection assay, immunoblotting, immunofluorescence, infection with mutant adenoviruses, transient transfection of E1A mutants","journal":"Virology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (RPA, WB, IF) combined with systematic mutagenesis of E1A in a single rigorous study","pmids":["12359426"],"is_preprint":false},{"year":2007,"finding":"Soluble GP73 is released from cells by proprotein convertase (furin)-mediated cleavage of its ectodomain. GP73 traffics from the cis-Golgi to the trans-Golgi network and endosomes, and cleavage occurs at a PC consensus site in the endosomal compartment. Alanine substitutions in the PC consensus site blocked both in vitro and in vivo cleavage, establishing the mechanism of GP73 secretion into serum.","method":"In vitro cleavage assay with purified furin, site-directed alanine mutagenesis, cleavage-specific antibody, subcellular fractionation/immunofluorescence of endosomes","journal":"Traffic","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic assay with purified furin, mutagenesis of the cleavage site, and in-cell localization studies all in one rigorous study","pmids":["17662025"],"is_preprint":false},{"year":2008,"finding":"At least two of three potential N-linked glycosylation sites on GP73 are occupied; the major glycoforms on secreted GP73 are bi-antennary with core fucose, with a smaller fraction of tri- and tetra-antennary structures, and approximately three-quarters of secreted GP73 is fucosylated, as determined by lectin affinity chromatography and mass spectrometry.","method":"Lectin affinity chromatography, mass spectrometry, recombinant GP73 expression","journal":"Journal of cellular biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mass spectrometry plus lectin chromatography in one study; single lab but two orthogonal analytical methods on endogenous and recombinant protein","pmids":["18004786"],"is_preprint":false},{"year":2008,"finding":"C-terminal truncation of GP73 in mice (gene-trap approach generating GP73^tr/tr) causes reduced survival, focal segmental glomerulosclerosis, hyaline thrombi in kidneys, and microvesicular hepatic steatosis with nuclear membrane irregularities, indicating that the GP73 C-terminus is essential for normal epithelial cell function in kidney and liver.","method":"Gene trap mouse model, histopathology, immunohistochemistry","journal":"International journal of clinical and experimental pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function in vivo model with defined phenotypic readout, single lab","pmids":["18830387"],"is_preprint":false},{"year":2010,"finding":"The Golgi localization of GOLPH2/GOLM1 is determined by its transmembrane domain combined with a positively charged residue in the cytoplasmic N-terminal tail; the C-terminal luminal domain is dispensable for Golgi targeting. Additionally, both endogenous and secreted GOLPH2 exist as disulfide-bonded dimers, and the coiled-coil domain is sufficient for dimerization.","method":"Truncation mutant panel, immunofluorescence microscopy, non-reducing SDS-PAGE, domain deletion analysis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — systematic domain-deletion mutagenesis with direct localization readout and biochemical dimerization assay, single lab but multiple orthogonal approaches","pmids":["22140547"],"is_preprint":false},{"year":2010,"finding":"GOLPH2/GOLM1 interacts with secretory clusterin (sCLU); the coiled-coil domain of GOLPH2 is sufficient for binding to sCLU, confirmed by yeast two-hybrid screening, intracellular co-immunoprecipitation, and co-localization in the Golgi.","method":"Yeast two-hybrid, co-immunoprecipitation, co-localization by immunofluorescence","journal":"Molecular biology reports","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — yeast two-hybrid plus co-IP plus co-localization in single lab; multiple methods but no functional mutagenesis or rescue","pmids":["20842452"],"is_preprint":false},{"year":2012,"finding":"IL-6 and oncostatin M (OSM) upregulate GP73 mRNA and protein in hepatoma (HepG2) cells via the shared receptor subunit gp130 and correlate with increased STAT3 phosphorylation; maximal induction requires new protein synthesis, suggesting indirect transcriptional regulators are involved.","method":"Cytokine treatment of HepG2 cells, Western blot, STAT3 phosphorylation analysis, protein synthesis inhibition with cycloheximide","journal":"Cancer biomarkers","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based mechanistic experiments with signaling pathway readouts and inhibitor controls, single lab","pmids":["23144154"],"is_preprint":false},{"year":2012,"finding":"The GOLPH2/GOLM1 promoter (2599 bp fragment) is TATA-less and maintains epithelial specificity. A repressive region (−864 to −734 bp), a positive regulatory region (−734 to −421 bp), and a core promoter region (−421 to −79 bp) were identified by deletion analysis. Adenoviral E1A activates GOLPH2 via its CtBP interaction domain; a GC-box motif (−89 to −83 bp) in the core promoter partly mediates E1A transactivation.","method":"Promoter cloning, deletion analysis, luciferase reporter assay, E1A transient transfection","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic promoter deletion plus reporter assay plus E1A mutant analysis, single lab","pmids":["22542941"],"is_preprint":false},{"year":2014,"finding":"Epithelium-specific ETS transcription factor ESE-1 directly binds the GP73 promoter and activates GP73 transcription. Both ESE-1 and GP73 are co-induced by IL-1β in hepatocellular carcinoma cells and during liver inflammation in vivo; knockdown of ESE-1 reduces GP73 expression.","method":"Promoter reporter assay, ChIP (direct binding to GP73 promoter), siRNA knockdown, overexpression, in vivo liver inflammation model","journal":"Cell & bioscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating direct transcription factor binding, supported by gain- and loss-of-function experiments, single lab","pmids":["25530841"],"is_preprint":false},{"year":2014,"finding":"GP73 enhances HCV secretion through its coiled-coil domain and by interacting with apolipoprotein E (ApoE), a host factor required for HCV secretion; GP73 overexpression or knockdown had no effect on HCV entry, protein translation, RNA replication, or assembly, placing GP73 specifically in the secretion step.","method":"Co-immunoprecipitation (GP73-ApoE interaction), GP73 overexpression/knockdown in HCV replicon and infected cell systems, domain deletion (coiled-coil mutant)","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain-mapping combined with Co-IP and systematic step-by-step HCV lifecycle assays, single lab","pmids":["24608522"],"is_preprint":false},{"year":2015,"finding":"mTORC1 positively regulates GP73 expression in HCC and other cancer cell lines; rapamycin (mTORC1 inhibitor) reduces GP73 levels in cancer cell lines and in xenograft tumors. GP73 overexpression promotes HCC cell proliferation and migration in vitro and accelerates xenograft tumor growth and metastasis in mice; GP73 knockout mice show reduced liver damage after diethylnitrosamine administration.","method":"Retroviral GP73 overexpression, shRNA knockdown, GP73 knockout mice, xenograft mouse models, rapamycin treatment, microarray gene expression, PTEN-null MEFs with constitutively active mTOR","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal approaches (KO mice, KD, OE, pharmacological inhibition, xenograft) in a single comprehensive study","pmids":["25980751"],"is_preprint":false},{"year":2016,"finding":"GOLM1 selectively interacts with EGFR and other RTKs and functions as a cargo adaptor to anchor EGFR/RTKs on the trans-Golgi network (TGN) and recycle them back to the plasma membrane, leading to prolonged downstream kinase activation and promoting HCC metastasis.","method":"Co-immunoprecipitation (GOLM1-EGFR interaction), gain- and loss-of-function studies, RTK recycling assays, gene expression profiling of HCC tissues","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, gain- and loss-of-function with defined molecular mechanism, replicated in multiple cell lines and in vivo","pmids":["27569582"],"is_preprint":false},{"year":2016,"finding":"N-glycosylation of GP73 at Asn144 reduces hepatocellular carcinoma cell motility and invasiveness; removal of N-glycans at Asn144 by site-directed mutagenesis enhances cell migration and invasion, possibly by altering cell membrane glycosylation and cell adhesion. Three N-glycosylation sites were identified (Asn109, Asn144, Asn398) by mass spectrometry, with five glycoforms at Asn144.","method":"Mass spectrometry for glycosylation site mapping, lectin microarray, site-directed mutagenesis of Asn144, cell migration and invasion assays","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 1 / Moderate — site-directed mutagenesis combined with mass spectrometry and functional cell-based assays, single lab but multiple orthogonal methods","pmids":["26993603"],"is_preprint":false},{"year":2017,"finding":"GP73 acts as a negative regulator of innate immunity to facilitate HCV infection: upon HCV infection, MAVS recruits TRAF6 via TRAF-interacting motifs; TRAF6 then directly recruits GP73 to MAVS via GP73's coiled-coil domain. GP73 then promotes proteasome-dependent degradation of both MAVS and TRAF6, attenuating IFN-β and NF-κB signaling.","method":"Co-immunoprecipitation (GP73-MAVS, GP73-TRAF6), domain mapping (coiled-coil deletion), proteasome inhibitor experiments, IFN-β/NF-κB reporter assays, GP73 knockdown in primary human hepatocytes and Huh7 cells, rescue with shRNA-resistant GP73 mutant","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, domain mapping, proteasome inhibition, knockdown+rescue in primary cells; multiple orthogonal methods in single rigorous study","pmids":["28394926"],"is_preprint":false},{"year":2017,"finding":"GOLM1 promotes prostate cancer progression by activating the PI3K-AKT-mTOR signaling pathway; PI3K inhibitor BKM120 abrogates GOLM1's oncogenic effects on proliferation, migration, invasion, and apoptosis in PCa cell lines and xenograft models.","method":"GOLM1 overexpression and knockdown in PCa cell lines, xenograft mouse models, PI3K inhibitor treatment, Western blot for AKT/mTOR pathway components","journal":"The Prostate","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with pathway inhibitor rescue, in vitro and in vivo, single lab","pmids":["29181846"],"is_preprint":false},{"year":2017,"finding":"PDGFA/PDGFRα signaling regulates GOLM1 expression; GOLM1 in turn promotes glioma progression through activation of AKT. GOLM1 is a key element in the PDGFA/PDGFRα-mediated AKT activation cascade, as demonstrated by PDGFRα inhibitor AG1296 and AKT inhibitor MK-2206 experiments.","method":"siRNA knockdown and lentiviral overexpression of GOLM1 in glioma cells, PDGFRα inhibitor (AG1296), AKT inhibitor (MK-2206), membrane-based kinase antibody array, orthotopic implantation in vivo","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic gain/loss-of-function, pathway inhibitor experiments, in vivo validation, single lab","pmids":["29282077"],"is_preprint":false},{"year":2019,"finding":"c-Myc transcriptionally activates GP73 in a mildly hypoxic microenvironment; GP73 then interacts with intracellular MMP-7 via its cytoplasmic domain and facilitates MMP-7 trafficking and secretion, promoting HCC cell metastasis.","method":"ChIP assay (c-Myc binding to GP73 promoter), co-immunoprecipitation (GP73-MMP-7), cytoplasmic domain interaction mapping, MMP-7 secretion assays, cell invasion assays","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for transcriptional regulation and Co-IP for direct protein interaction, single lab","pmids":["31591387"],"is_preprint":false},{"year":2019,"finding":"mTOR negatively regulates miR-145 expression; miR-145 directly inhibits GOLM1 by targeting its coding sequence. GOLM1-enriched exosomes activate the GSK-3β/MMP signaling axis in recipient cells, accelerating proliferation and migration.","method":"miR-145 target validation (luciferase reporter assay targeting CDS of GOLM1), exosome isolation and transfer assay, GSK-3β/MMP pathway analysis, in vivo mouse HCC model","journal":"Journal of genetics and genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase reporter validation plus exosome functional transfer assay plus in vivo, single lab","pmids":["31186161"],"is_preprint":false},{"year":2019,"finding":"GP73 is a direct transcriptional target of TGF-β1; upregulated GP73 inhibits TGF-β-Smad-mediated growth suppression while enhancing ERK/AKT signaling downstream of TGF-β1. Mechanistically, GP73 upregulates lipid rafts/caveolin-1, which mediates the switch from Smad to non-Smad TGF-β1 signaling.","method":"TGF-β1 reporter assay, GP73 overexpression/knockdown, Western blot for Smad and ERK/AKT phosphorylation, lipid raft isolation, caveolin-1 staining","journal":"Biochimica et biophysica acta. Molecular cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic signaling experiments with lipid raft biochemistry and gain/loss-of-function, single lab","pmids":["30615900"],"is_preprint":false},{"year":2020,"finding":"GOLM1 upregulates PD-L1 expression via the EGFR/STAT3 signaling pathway in HCC cells: GOLM1 enhances EGFR levels, which promotes STAT3 phosphorylation, which in turn increases PD-L1 transcription.","method":"GOLM1 overexpression/knockdown, Western blot for EGFR and p-STAT3, STAT3 inhibitor treatment, PD-L1 expression analysis","journal":"American journal of cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with pharmacological pathway inhibition, single lab","pmids":["33294262"],"is_preprint":false},{"year":2021,"finding":"GOLM1 promotes COP9 signalosome 5-mediated PD-L1 deubiquitination in HCC cells, stabilizing PD-L1, and suppresses Rab27b expression to increase transport of PD-L1 into exosomes. Exosomes containing PD-L1 from GOLM1-high HCC cells upregulate PD-L1 on macrophages, inducing CD8+ T cell suppression.","method":"Gain- and loss-of-function studies, co-culture assays with exosomes, Rab27b expression analysis, ubiquitination/deubiquitination assays, flow cytometry for CD8+ T cells","journal":"Signal transduction and targeted therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway studies with exosome transfer assay and in vivo mouse model, single lab","pmids":["34795203"],"is_preprint":false},{"year":2021,"finding":"GOLM1 depletion in intestinal epithelial cells leads to aberrant Notch pathway activation, interfering with IEC differentiation, maturation, and lineage commitment. GOLM1-deficient mice are susceptible to mucosal inflammation and colitis-induced epithelial damage; pharmacological inhibition of Notch alleviates epithelial lesions in GOLM1-deficient mice, placing GOLM1 upstream of Notch equilibrium.","method":"GOLM1 knockout mice (colitis models), Notch pathway inhibition (gamma-secretase inhibitor), histopathology, marker gene expression analysis","journal":"Signal transduction and targeted therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis via pharmacological rescue in KO mice, single lab","pmids":["33850109"],"is_preprint":false},{"year":2021,"finding":"GP73 is a Rab GTPase-activating protein (RabGAP) with TBC domain activity that regulates ApoB export from hepatocytes; liver-specific GP73-overexpressing mice develop non-obese NAFLD (intrahepatic lipid accumulation, insulin resistance, reduced body weight), a phenotype not recapitulated by a GAP-inactive GP73 mutant. Metformin inactivates the GAP activity of GP73 and alleviates this non-obese NAFLD phenotype.","method":"RabGAP activity assay, TBC-domain mutagenesis (GAP-inactive mutant), liver-specific GP73 transgenic mice, high-fat diet NAFLD comparison, metformin treatment, ApoB export assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — enzymatic GAP activity assay combined with active-site mutagenesis, transgenic mouse model, pharmacological rescue with metformin, multiple orthogonal methods in one study","pmids":["34853313"],"is_preprint":false},{"year":2021,"finding":"GOLM1 promotes liver fibrosis-induced PD-L1 upregulation and immune escape in HCC via the EGFR signaling pathway; GOLM1 levels are increased in fibrotic livers and hepatocyte-specific GOLM1 transgenic mice show decreased CD8+ T cell infiltration and increased PD-L1 in tumors during chemical carcinogenesis. EGFR inhibitors improve immunotherapy efficacy.","method":"Hepatocyte-specific GOLM1 transgenic mice, CCl4-induced fibrosis model, EGFR inhibitor treatment, immunohistochemistry for CD8+ T cells and PD-L1, EGFR pathway Western blot","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic mouse gain-of-function combined with pharmacological inhibitor rescue, single lab","pmids":["33992711"],"is_preprint":false},{"year":2021,"finding":"GP73 directly binds AFP and increases AFP secretion from HCC cells; extracellular GP73 independently promotes HCC cell proliferation and metastasis, and extracellular GP73 and AFP synergize to enhance HCC malignancy and drug resistance to sorafenib.","method":"Co-immunoprecipitation (GP73-AFP direct binding), GP73 overexpression/knockdown, AFP secretion assays, cell proliferation and metastasis assays, sorafenib resistance assay","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding demonstrated by Co-IP, functional secretion assay, single lab","pmids":["34650031"],"is_preprint":false},{"year":2021,"finding":"GOLM1 overexpression enhances phosphorylation of p53 at Ser315 and inhibits p53 tetramer formation, reducing p53 tumor-suppressor function; this effect is associated with GOLM1-driven lung cancer aggressiveness as shown by phosphoproteomic analysis.","method":"Phosphoproteomics (phosphoprotein array), Western blot for p53 phospho-Ser315, p53 tetramer native gel assay, GOLM1 overexpression/knockdown, xenograft in vivo","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphoproteomics combined with biochemical p53 tetramer assay, single lab","pmids":["33649292"],"is_preprint":false},{"year":2022,"finding":"Cholesterol suppresses GOLM1-dependent autophagic degradation of RTKs: GOLM1 mediates selective autophagy of RTKs by interacting with LC3 through an LC3-interacting region (LIR) motif, and this interaction is regulated by a cholesterol-mTORC1 axis. High cholesterol activates mTORC1 to suppress the LIR-LC3 interaction, switching GOLM1 from promoting RTK degradation to promoting RTK recycling.","method":"Co-immunoprecipitation (GOLM1-LC3), LIR motif mutagenesis, autophagic flux assays, cholesterol manipulation, mTORC1 inhibition, statin treatment in vivo with RTK inhibitors","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mutagenesis of LIR motif combined with Co-IP, autophagic flux assays, pharmacological manipulation of cholesterol and mTORC1, and in vivo combination therapy experiments","pmids":["35443161"],"is_preprint":false},{"year":2022,"finding":"GP73 functions as a glucogenic hormone: fasting induces GP73 secretion from multiple tissues; secreted GP73 stimulates hepatic gluconeogenesis through the cAMP/PKA signaling pathway. SARS-CoV-2 infection increases GP73 secretion, and GP73 antibody blockade inhibits excessive gluconeogenesis in SARS-CoV-2-infected mice and lowers fasting blood glucose.","method":"GP73 recombinant protein treatment of hepatocytes, cAMP/PKA pathway inhibitors, GP73-neutralizing antibody in mice, mouse-adapted SARS-CoV-2 infection model, fasting experiments in multiple tissues","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct recombinant protein activity assay demonstrating gluconeogenic effect, signaling pathway identification, in vivo antibody neutralization with multiple disease models","pmids":["34992299"],"is_preprint":false},{"year":2024,"finding":"ASGR1 (asialoglycoprotein receptor 1) directly binds GP73 and facilitates its lysosomal degradation; ASGR1 deficiency increases circulating GP73 levels. Elevated GP73 then interacts with BIP/GRP78 to activate endoplasmic reticulum stress, causing liver injury. GP73 neutralization attenuates ASGR1-deficiency-induced liver injuries.","method":"Co-immunoprecipitation (ASGR1-GP73, GP73-BIP), lysosomal degradation assays, ASGR1 knockout and overexpression in mice, GP73-neutralizing antibody rescue experiments, acetaminophen and CCl4 liver injury models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — reciprocal Co-IP demonstrating direct binding to two partners, genetic KO and OE with antibody rescue, multiple in vivo injury models","pmids":["38459023"],"is_preprint":false},{"year":2024,"finding":"GP73 promotes HCC tumor angiogenesis by directly binding STAT3 and simultaneously enhancing GRP78-induced endoplasmic reticulum stress; GP73 is activated transcriptionally by histone lactylation and c-Myc, and GP73-mediated STAT3 phosphorylation potentiates pro-angiogenic functions.","method":"Co-immunoprecipitation (GP73-STAT3), ChIP for c-Myc and histone lactylation at GP73 locus, in vitro and in vivo angiogenesis assays, single-cell and spatial transcriptomics","journal":"Research (Washington, D.C.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for direct binding, ChIP for transcriptional regulation, in vitro and in vivo functional assays, single lab","pmids":["38939041"],"is_preprint":false},{"year":2012,"finding":"In Xenopus, morpholino-mediated knockdown of golph2/GOLM1 causes edema, enhanced Nephrin expression in the glomus, reduced expression of pronephric tubule/duct markers (atp1b1, ClC-K, NKCC2, NBC1), and expanded WT1 expression, demonstrating that GOLPH2 is required for normal pronephros development by modulating WT1-dependent differentiation of the pronephric field.","method":"Morpholino knockdown in Xenopus embryos, in situ hybridization for pronephric marker genes, immunostaining for WT1","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — morpholino loss-of-function in a vertebrate model organism with multiple defined marker readouts, single lab; Xenopus golph2 protein confirmed to dimerize and localize to Golgi like human GOLPH2","pmids":["22719994"],"is_preprint":false},{"year":2022,"finding":"GOLM1 depletion in Huh-7 HCC cells causes aberrant accumulation of ceramides, hexosylceramides, dihexosylceramides, sphinganine, sphingosine, ceramide phosphate, and cholesteryl esters, with reduction in phosphatidylethanolamines, demonstrating that GOLM1 is required for normal cellular sphingolipid homeostasis. GOLM1 depletion also disrupts Golgi structure and reduces mitochondrial oxygen consumption, and impairs cell proliferation.","method":"siRNA-mediated GOLM1 knockdown, mass spectrometric lipidomics, Seahorse extracellular flux analysis, electron microscopy, immunofluorescence for Golgi structure, cell cycle analysis","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (lipidomics, EM, Seahorse) in single lab KD study","pmids":["35948172"],"is_preprint":false},{"year":2018,"finding":"GP73 promotes epithelial-mesenchymal transition (EMT) and invasion in HCC partly by activating the TGF-β1/Smad2 signaling pathway; GP73 enhances p-Smad2 and p-Smad3 levels by mediating TGF-β1. Blocking the TGF-β1/Smad pathway with SB431542 partially reverses GP73-driven EMT, but GP73 retains some pro-EMT activity through additional pathways.","method":"GP73 overexpression/knockdown in HCC cell lines, Western blot for p-Smad2/3, TGF-β1/Smad pathway inhibitor (SB431542), in vitro invasion assay, in vivo metastasis model","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway rescue combined with gain/loss-of-function, single lab","pmids":["29365054"],"is_preprint":false}],"current_model":"GOLM1/GP73 is a type II Golgi transmembrane glycoprotein that (1) is cleaved by furin-family proprotein convertases in the endosomal compartment to generate a secreted ectodomain; (2) acts as a cargo adaptor on the trans-Golgi network to recycle EGFR/RTKs to the plasma membrane, prolonging downstream signaling, and also mediates selective LC3-dependent autophagic degradation of RTKs in a cholesterol- and mTORC1-regulated manner; (3) possesses TBC-domain Rab-GAP activity that controls ApoB export and drives non-obese NAFLD; (4) functions as a circulating glucogenic hormone that stimulates hepatic gluconeogenesis via cAMP/PKA signaling; (5) interacts with MAVS/TRAF6 to promote their proteasomal degradation and suppress innate immune signaling; (6) regulates PD-L1 stability and exosomal transport to promote immune escape via EGFR/STAT3; (7) modulates sphingolipid homeostasis through its role in Golgi structure and trafficking; and (8) is transcriptionally regulated by c-Myc, ESE-1, TGF-β1, IL-6/OSM via STAT3, and the adenoviral E1A CtBP-interaction domain."},"narrative":{"mechanistic_narrative":"GOLM1 (GP73/GOLPH2) is a type II Golgi transmembrane glycoprotein that couples Golgi trafficking control to receptor signaling, secretion, and systemic metabolism, and is repeatedly co-opted to drive hepatocellular carcinoma and other cancers [PMID:10831838, PMID:27569582, PMID:25980751]. Its Golgi residence is specified by the transmembrane domain plus a positively charged cytoplasmic residue, and the coiled-coil domain mediates disulfide-bonded dimerization and most protein-protein interactions [PMID:22140547]. GOLM1 traffics from the cis-Golgi to the trans-Golgi network and endosomes, where furin-family proprotein convertases cleave a luminal consensus site to release a heavily fucosylated, N-glycosylated soluble ectodomain into serum [PMID:17662025, PMID:18004786]. At the TGN, GOLM1 acts as a cargo adaptor that binds EGFR and other receptor tyrosine kinases to recycle them to the plasma membrane and prolong downstream kinase signaling, thereby promoting metastasis [PMID:27569582]; a cholesterol-mTORC1 axis toggles this activity, since GOLM1 also engages LC3 through an LIR motif to route RTKs into selective autophagic degradation when cholesterol and mTORC1 are low [PMID:35443161]. GOLM1 possesses TBC-domain Rab-GAP activity that controls hepatic ApoB export, and liver-specific overexpression drives non-obese NAFLD in a manner abolished by a GAP-inactive mutant and reversed by metformin [PMID:34853313]. The secreted ectodomain functions as a fasting-induced glucogenic hormone that stimulates hepatic gluconeogenesis via cAMP/PKA signaling [PMID:34992299]. GOLM1 additionally suppresses innate immunity by being recruited to MAVS via TRAF6 to drive proteasomal degradation of both, dampening IFN-β and NF-κB signaling [PMID:28394926], and promotes immune escape by stabilizing and exosomally exporting PD-L1 through EGFR/STAT3 [PMID:33294262, PMID:34795203]. Across cancers GOLM1 is transcriptionally induced by c-Myc, ESE-1, TGF-β1, and IL-6/OSM-STAT3 signaling, and these inputs feed forward into PI3K-AKT-mTOR, EGFR, and STAT3 signaling axes [PMID:25530841, PMID:23144154, PMID:30615900, PMID:29181846, PMID:27569582].","teleology":[{"year":2000,"claim":"Established the molecular identity and disease context of GP73: an integral Golgi membrane protein normally restricted from hepatocytes but induced by viral infection, framing it as a liver-disease-associated Golgi protein.","evidence":"In vitro transcription-translation, epitope-tag immunolocalization, Northern blot and IHC across epithelial tissues","pmids":["10831838"],"confidence":"High","gaps":["No molecular function assigned","Mechanism of viral induction undefined"]},{"year":2002,"claim":"Defined how viral infection induces GP73, showing the adenoviral E1A CtBP-interaction domain is required, linking GP73 expression to a specific transcriptional co-repressor pathway.","evidence":"RNase protection, immunoblot/IF, and infection with E1A mutant adenoviruses plus transient E1A transfection","pmids":["12359426"],"confidence":"High","gaps":["Did not map the cellular transcription factors recruited via CID","No endogenous viral context beyond adenovirus"]},{"year":2007,"claim":"Resolved the mechanism by which GP73 becomes a serum protein: furin-mediated cleavage at a PC consensus site in the endosomal compartment liberates the ectodomain, explaining its biomarker behavior.","evidence":"In vitro cleavage assay with purified furin, alanine mutagenesis of the cleavage site, cleavage-specific antibody and endosomal fractionation/IF","pmids":["17662025"],"confidence":"High","gaps":["Function of the secreted ectodomain not yet known","Regulation of cleavage rate unaddressed"]},{"year":2008,"claim":"Characterized GP73 glycosylation (predominantly core-fucosylated bi-antennary structures) and showed the C-terminus is essential in vivo, with truncation causing kidney and liver pathology.","evidence":"Lectin chromatography/MS on recombinant and secreted GP73; gene-trap GP73^tr/tr mouse histopathology","pmids":["18004786","18830387"],"confidence":"High","gaps":["Functional consequence of fucosylation undefined","Mechanism linking C-terminus to epithelial pathology unknown"]},{"year":2010,"claim":"Defined the structural determinants of GP73 — TM-plus-charged-residue Golgi targeting and coiled-coil-mediated dimerization — and identified secretory clusterin as an early binding partner.","evidence":"Truncation/domain-deletion mutants with IF localization and non-reducing SDS-PAGE; yeast two-hybrid, co-IP and co-localization for sCLU","pmids":["22140547","20842452"],"confidence":"Medium","gaps":["sCLU interaction lacks functional/rescue validation","Functional role of dimerization untested"]},{"year":2012,"claim":"Connected GP73 expression to inflammatory cytokine signaling and defined core promoter architecture, showing IL-6/OSM-gp130-STAT3 induction and E1A/GC-box-mediated transactivation.","evidence":"Cytokine treatment of HepG2 with cycloheximide controls; promoter deletion/luciferase reporter assays with E1A mutants; Xenopus golph2 morpholino developmental study","pmids":["23144154","22542941","22719994"],"confidence":"Medium","gaps":["Direct STAT3 binding to promoter not demonstrated","Vertebrate pronephros role mechanistically tied only to WT1 marker shifts"]},{"year":2014,"claim":"Identified direct transcription factors (ESE-1) and established a secretion-promoting role in HCV egress via the coiled-coil domain and ApoE interaction.","evidence":"ChIP and gain/loss-of-function for ESE-1; co-IP for GP73-ApoE plus stepwise HCV lifecycle assays with coiled-coil deletion","pmids":["25530841","24608522"],"confidence":"Medium","gaps":["Whether GP73 acts as a general secretion adaptor beyond HCV unaddressed","Single-lab ChIP for ESE-1"]},{"year":2015,"claim":"Placed GOLM1 in a feed-forward oncogenic loop with mTORC1 and demonstrated causal tumor-promoting roles in HCC using KO, KD, OE, and xenograft models.","evidence":"GP73 KO mice, shRNA, retroviral OE, rapamycin treatment, xenografts and DEN-induced liver damage","pmids":["25980751"],"confidence":"High","gaps":["Molecular effector of pro-tumor activity not yet defined at this stage"]},{"year":2016,"claim":"Defined GOLM1's signature molecular activity: a TGN cargo adaptor that binds EGFR/RTKs to recycle them to the plasma membrane and prolong kinase signaling; also linked Asn144 glycosylation to motility control.","evidence":"Reciprocal co-IP, RTK recycling assays, gain/loss-of-function in vivo; MS glycosite mapping with Asn144 mutagenesis and migration/invasion assays","pmids":["27569582","26993603"],"confidence":"High","gaps":["How adaptor selectivity for RTKs is determined unclear","Glycosylation effect on adhesion partners not identified"]},{"year":2017,"claim":"Extended GOLM1 oncogenic signaling to PI3K-AKT-mTOR and PDGFA/PDGFRα-AKT cascades in prostate cancer and glioma, and identified MMP-7 trafficking under c-Myc/hypoxia control.","evidence":"Gain/loss-of-function with PI3K (BKM120), PDGFRα (AG1296) and AKT (MK-2206) inhibitors, kinase arrays, xenograft/orthotopic models; ChIP for c-Myc and co-IP for GP73-MMP-7","pmids":["29181846","29282077","31591387"],"confidence":"Medium","gaps":["Whether AKT activation is direct or via RTK recycling not resolved","Single-lab studies per cancer type"]},{"year":2017,"claim":"Revealed an innate-immune-suppressive function: TRAF6-dependent recruitment of GP73 to MAVS drives proteasomal degradation of MAVS and TRAF6, attenuating antiviral signaling.","evidence":"Reciprocal co-IP, coiled-coil deletion mapping, proteasome inhibition, IFN-β/NF-κB reporters, knockdown+rescue in primary hepatocytes","pmids":["28394926"],"confidence":"High","gaps":["Whether GP73 recruits an E3 ligase or acts directly is undefined","Generality beyond HCV-triggered signaling untested"]},{"year":2019,"claim":"Connected GOLM1 to TGF-β1 signaling rewiring and exosomal communication, showing it switches TGF-β1 from Smad to non-Smad (ERK/AKT) output and exports pro-tumor cargo via exosomes regulated by mTOR/miR-145.","evidence":"TGF-β1 reporter, lipid raft/caveolin-1 biochemistry, Smad/ERK/AKT phospho-blots; miR-145 luciferase CDS targeting and exosome transfer assays in vivo","pmids":["30615900","31186161","29365054"],"confidence":"Medium","gaps":["Direct mechanism of Smad-to-nonSmad switch beyond lipid raft correlation unclear","Exosomal cargo selectivity undefined"]},{"year":2020,"claim":"Established GOLM1 as a driver of immune escape, upregulating and stabilizing PD-L1 via EGFR/STAT3 and routing PD-L1 into exosomes through CSN5 deubiquitination and Rab27b suppression.","evidence":"Gain/loss-of-function with STAT3 inhibition; ubiquitination assays, Rab27b analysis, exosome co-culture and CD8+ T cell flow cytometry; fibrosis transgenic models with EGFR inhibitors","pmids":["33294262","34795203","33992711"],"confidence":"Medium","gaps":["Direct vs RTK-recycling-mediated EGFR effect not separated","Most readouts single-lab"]},{"year":2021,"claim":"Assigned GOLM1 an intrinsic enzymatic activity: TBC-domain Rab-GAP function controlling hepatocyte ApoB export and driving non-obese NAFLD, pharmacologically targetable by metformin.","evidence":"RabGAP activity assay, GAP-inactive TBC-domain mutant, liver-specific transgenic mice, ApoB export assays, metformin rescue","pmids":["34853313"],"confidence":"High","gaps":["Specific Rab substrate(s) not definitively identified","Link between GAP activity and adaptor/autophagy roles unclear"]},{"year":2021,"claim":"Demonstrated developmental and homeostatic roles of GOLM1 in epithelium, p53 regulation, and AFP secretion, broadening its biology beyond signaling adaptor functions.","evidence":"GOLM1 KO mice colitis models with Notch (γ-secretase) inhibition; phosphoproteomics and p53 tetramer assays; co-IP for GP73-AFP and secretion assays","pmids":["33850109","33649292","34650031"],"confidence":"Medium","gaps":["Mechanism by which GOLM1 restrains Notch undefined","Direct vs indirect control of p53 Ser315 phosphorylation unresolved"]},{"year":2022,"claim":"Unified the recycling-vs-degradation switch and identified a Golgi/lipid-homeostasis function: GOLM1 binds LC3 via an LIR motif for selective RTK autophagy under cholesterol-mTORC1 control, and is required for sphingolipid balance and Golgi integrity.","evidence":"Co-IP, LIR mutagenesis, autophagic flux, cholesterol/mTORC1 manipulation, in vivo statin+RTK inhibitor therapy; lipidomics, EM, Seahorse on GOLM1-depleted Huh-7 cells","pmids":["35443161","35948172"],"confidence":"High","gaps":["How lipid homeostasis defects relate to RTK adaptor function unclear","In vivo relevance of sphingolipid changes untested"]},{"year":2022,"claim":"Identified the secreted ectodomain as a fasting-induced glucogenic hormone acting through hepatic cAMP/PKA, with pathological elevation in SARS-CoV-2 infection.","evidence":"Recombinant GP73 hepatocyte assays, cAMP/PKA inhibitors, neutralizing antibody in mouse-adapted SARS-CoV-2 and fasting models","pmids":["34992299"],"confidence":"High","gaps":["Receptor for circulating GP73 on hepatocytes not identified","Relationship to RabGAP-driven hepatic phenotype unclear"]},{"year":2024,"claim":"Defined turnover and downstream stress signaling of circulating GP73: ASGR1 binding routes GP73 to lysosomal degradation, while elevated GP73 binds BIP/GRP78 to trigger ER stress and liver injury, and binds STAT3 to drive tumor angiogenesis.","evidence":"Reciprocal co-IP (ASGR1-GP73, GP73-BIP, GP73-STAT3), ASGR1 KO/OE mice with neutralizing antibody rescue in liver injury models; ChIP for c-Myc/histone lactylation and angiogenesis assays","pmids":["38459023","38939041"],"confidence":"High","gaps":["Whether ER-stress and STAT3 effects are mediated by secreted vs intracellular GP73 not fully resolved","Histone-lactylation regulation single-lab"]},{"year":null,"claim":"It remains unresolved how GOLM1's distinct activities — TGN cargo adaptor, LIR-dependent autophagy receptor, TBC Rab-GAP, and secreted glucogenic hormone — are coordinated within one protein, and which Rab substrate and which hepatocyte receptor underlie its enzymatic and hormonal functions.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model integrating TBC domain, coiled-coil, and LIR motif","Rab-GAP substrate unidentified","Receptor mediating circulating GP73 hormone action unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[12,27]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[23,14]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[28]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[5]}],"localization":[{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[0,5,2]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[2]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[2,28]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[12]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[12,20,15]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[27]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[14,21]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[23,28,32]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[12,2,21]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[11,23]}],"complexes":[],"partners":["EGFR","MAVS","TRAF6","MAP1LC3","ASGR1","HSPA5","STAT3","APOE"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8NBJ4","full_name":"Golgi membrane protein 1","aliases":["Golgi membrane protein GP73","Golgi phosphoprotein 2"],"length_aa":401,"mass_kda":45.3,"function":"Unknown. Cellular response protein to viral infection","subcellular_location":"Golgi apparatus, cis-Golgi network membrane","url":"https://www.uniprot.org/uniprotkb/Q8NBJ4/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GOLM1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GOLM1","total_profiled":1310},"omim":[{"mim_id":"607461","title":"DYMECLIN; DYM","url":"https://www.omim.org/entry/607461"},{"mim_id":"606804","title":"GOLGI MEMBRANE PROTEIN 1; GOLM1","url":"https://www.omim.org/entry/606804"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Golgi apparatus","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"stomach 1","ntpm":374.5}],"url":"https://www.proteinatlas.org/search/GOLM1"},"hgnc":{"alias_symbol":["GP73","FLJ23608","bA379P1.3"],"prev_symbol":["GOLPH2","C9orf155"]},"alphafold":{"accession":"Q8NBJ4","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8NBJ4","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8NBJ4-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8NBJ4-F1-predicted_aligned_error_v6.png","plddt_mean":64.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GOLM1","jax_strain_url":"https://www.jax.org/strain/search?query=GOLM1"},"sequence":{"accession":"Q8NBJ4","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8NBJ4.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8NBJ4/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8NBJ4"}},"corpus_meta":[{"pmid":"16137783","id":"PMC_16137783","title":"GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma.","date":"2005","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/16137783","citation_count":299,"is_preprint":false},{"pmid":"10831838","id":"PMC_10831838","title":"GP73, a novel Golgi-localized protein upregulated by viral infection.","date":"2000","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/10831838","citation_count":219,"is_preprint":false},{"pmid":"20876776","id":"PMC_20876776","title":"Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma.","date":"2010","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/20876776","citation_count":204,"is_preprint":false},{"pmid":"12029628","id":"PMC_12029628","title":"Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease.","date":"2002","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/12029628","citation_count":187,"is_preprint":false},{"pmid":"27569582","id":"PMC_27569582","title":"GOLM1 Modulates EGFR/RTK Cell-Surface Recycling to Drive Hepatocellular Carcinoma Metastasis.","date":"2016","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/27569582","citation_count":186,"is_preprint":false},{"pmid":"34795203","id":"PMC_34795203","title":"GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages.","date":"2021","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34795203","citation_count":163,"is_preprint":false},{"pmid":"20625772","id":"PMC_20625772","title":"AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC.","date":"2010","source":"Journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/20625772","citation_count":156,"is_preprint":false},{"pmid":"15180730","id":"PMC_15180730","title":"Disease- and cell-specific expression of GP73 in human liver disease.","date":"2004","source":"The American journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/15180730","citation_count":110,"is_preprint":false},{"pmid":"19291786","id":"PMC_19291786","title":"Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas.","date":"2009","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19291786","citation_count":108,"is_preprint":false},{"pmid":"24284362","id":"PMC_24284362","title":"The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer.","date":"2013","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24284362","citation_count":106,"is_preprint":false},{"pmid":"17662025","id":"PMC_17662025","title":"Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma.","date":"2007","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/17662025","citation_count":104,"is_preprint":false},{"pmid":"18953438","id":"PMC_18953438","title":"Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer.","date":"2008","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18953438","citation_count":94,"is_preprint":false},{"pmid":"30745298","id":"PMC_30745298","title":"Evaluation of Salivary Exosomal Chimeric GOLM1-NAA35 RNA as a Potential Biomarker in Esophageal Carcinoma.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30745298","citation_count":82,"is_preprint":false},{"pmid":"25980751","id":"PMC_25980751","title":"mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.","date":"2015","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/25980751","citation_count":76,"is_preprint":false},{"pmid":"18004786","id":"PMC_18004786","title":"N-linked glycosylation of the liver cancer biomarker GP73.","date":"2008","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18004786","citation_count":72,"is_preprint":false},{"pmid":"30742421","id":"PMC_30742421","title":"Ratiometric Immunosensor for GP73 Detection Based on the Ratios of Electrochemiluminescence and Electrochemical Signal Using DNA Tetrahedral Nanostructure as the Carrier of Stable Reference Signal.","date":"2019","source":"Analytical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30742421","citation_count":72,"is_preprint":false},{"pmid":"18543251","id":"PMC_18543251","title":"GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus.","date":"2008","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/18543251","citation_count":66,"is_preprint":false},{"pmid":"19399652","id":"PMC_19399652","title":"GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population.","date":"2009","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19399652","citation_count":62,"is_preprint":false},{"pmid":"29181846","id":"PMC_29181846","title":"GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.","date":"2017","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/29181846","citation_count":60,"is_preprint":false},{"pmid":"31186161","id":"PMC_31186161","title":"mTOR/miR-145-regulated exosomal GOLM1 promotes hepatocellular carcinoma through augmented GSK-3β/MMPs.","date":"2019","source":"Journal of genetics and genomics = Yi chuan xue bao","url":"https://pubmed.ncbi.nlm.nih.gov/31186161","citation_count":55,"is_preprint":false},{"pmid":"21663469","id":"PMC_21663469","title":"Golgi protein 73(GP73), a useful serum marker in liver diseases.","date":"2011","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21663469","citation_count":54,"is_preprint":false},{"pmid":"38939041","id":"PMC_38939041","title":"Integrating Single-Cell and Spatial Transcriptomics to Uncover and Elucidate GP73-Mediated Pro-Angiogenic Regulatory Networks in Hepatocellular Carcinoma.","date":"2024","source":"Research (Washington, D.C.)","url":"https://pubmed.ncbi.nlm.nih.gov/38939041","citation_count":52,"is_preprint":false},{"pmid":"22140547","id":"PMC_22140547","title":"The Golgi localization of GOLPH2 (GP73/GOLM1) is determined by the transmembrane and cytoplamic sequences.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22140547","citation_count":52,"is_preprint":false},{"pmid":"34992299","id":"PMC_34992299","title":"GP73 is a glucogenic hormone contributing to SARS-CoV-2-induced hyperglycemia.","date":"2022","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34992299","citation_count":51,"is_preprint":false},{"pmid":"23144154","id":"PMC_23144154","title":"Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73.","date":"2012","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/23144154","citation_count":50,"is_preprint":false},{"pmid":"20501332","id":"PMC_20501332","title":"Up-regulated Golgi phosphoprotein 2 (GOLPH2) expression in lung adenocarcinoma tissue.","date":"2010","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20501332","citation_count":49,"is_preprint":false},{"pmid":"18830387","id":"PMC_18830387","title":"Decreased survival and hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2).","date":"2008","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18830387","citation_count":47,"is_preprint":false},{"pmid":"29256057","id":"PMC_29256057","title":"The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review.","date":"2018","source":"Clinical reviews in allergy & immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29256057","citation_count":46,"is_preprint":false},{"pmid":"33992711","id":"PMC_33992711","title":"Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/33992711","citation_count":45,"is_preprint":false},{"pmid":"28394926","id":"PMC_28394926","title":"GP73 represses host innate immune response to promote virus replication by facilitating MAVS and TRAF6 degradation.","date":"2017","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/28394926","citation_count":45,"is_preprint":false},{"pmid":"23119104","id":"PMC_23119104","title":"GP73 expression and its significance in the diagnosis of hepatocellular carcinoma: a review.","date":"2012","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23119104","citation_count":44,"is_preprint":false},{"pmid":"38459023","id":"PMC_38459023","title":"Deficiency of ASGR1 promotes liver injury by increasing GP73-mediated hepatic endoplasmic reticulum stress.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38459023","citation_count":43,"is_preprint":false},{"pmid":"33850109","id":"PMC_33850109","title":"GOLM1 restricts colitis and colon tumorigenesis by ensuring Notch signaling equilibrium in intestinal homeostasis.","date":"2021","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33850109","citation_count":42,"is_preprint":false},{"pmid":"23418424","id":"PMC_23418424","title":"Serum GP73, a marker for evaluating progression in patients with chronic HBV infections.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23418424","citation_count":40,"is_preprint":false},{"pmid":"23686365","id":"PMC_23686365","title":"Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma.","date":"2013","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/23686365","citation_count":37,"is_preprint":false},{"pmid":"29282077","id":"PMC_29282077","title":"PDGFA/PDGFRα-regulated GOLM1 promotes human glioma progression through activation of AKT.","date":"2017","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/29282077","citation_count":36,"is_preprint":false},{"pmid":"19596473","id":"PMC_19596473","title":"Hepatocyte GP73 expression in Wilson disease.","date":"2009","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/19596473","citation_count":36,"is_preprint":false},{"pmid":"28419971","id":"PMC_28419971","title":"miR-493-5p suppresses hepatocellular carcinoma cell proliferation through targeting GP73.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/28419971","citation_count":35,"is_preprint":false},{"pmid":"25168922","id":"PMC_25168922","title":"Serum gp73 is also a biomarker for diagnosing cirrhosis in population with chronic HBV infection.","date":"2014","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25168922","citation_count":35,"is_preprint":false},{"pmid":"20842452","id":"PMC_20842452","title":"Golgi phosphoprotein 2 (GOLPH2/GP73/GOLM1) interacts with secretory clusterin.","date":"2010","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/20842452","citation_count":34,"is_preprint":false},{"pmid":"25980438","id":"PMC_25980438","title":"A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25980438","citation_count":33,"is_preprint":false},{"pmid":"19014428","id":"PMC_19014428","title":"GOLPH2 expression in renal cell cancer.","date":"2008","source":"BMC urology","url":"https://pubmed.ncbi.nlm.nih.gov/19014428","citation_count":31,"is_preprint":false},{"pmid":"32196610","id":"PMC_32196610","title":"LncRNA MALAT1 knockdown inhibits cell migration and invasion by suppressing autophagy through miR-384/GOLM1 axis in glioma.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32196610","citation_count":31,"is_preprint":false},{"pmid":"29365054","id":"PMC_29365054","title":"GP73 promotes epithelial-mesenchymal transition and invasion partly by activating TGF-β1/Smad2 signaling in hepatocellular carcinoma.","date":"2018","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/29365054","citation_count":31,"is_preprint":false},{"pmid":"34853313","id":"PMC_34853313","title":"GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34853313","citation_count":31,"is_preprint":false},{"pmid":"24137480","id":"PMC_24137480","title":"Serum GP73 is complementary to AFP and GGT-II for the diagnosis of hepatocellular carcinoma.","date":"2013","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/24137480","citation_count":31,"is_preprint":false},{"pmid":"12359426","id":"PMC_12359426","title":"Upregulation of the Golgi protein GP73 by adenovirus infection requires the E1A CtBP interaction domain.","date":"2002","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/12359426","citation_count":31,"is_preprint":false},{"pmid":"21517136","id":"PMC_21517136","title":"A study of diagnostic value of golgi protein GP73 and its genetic assay in primary hepatic carcinoma.","date":"2011","source":"Technology in cancer research & treatment","url":"https://pubmed.ncbi.nlm.nih.gov/21517136","citation_count":30,"is_preprint":false},{"pmid":"24243830","id":"PMC_24243830","title":"Aberrant chimeric RNA GOLM1-MAK10 encoding a secreted fusion protein as a molecular signature for human esophageal squamous cell carcinoma.","date":"2013","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24243830","citation_count":30,"is_preprint":false},{"pmid":"30695018","id":"PMC_30695018","title":"Golgi Membrane Protein 1 (GOLM1) Promotes Growth and Metastasis of Breast Cancer Cells via Regulating Matrix Metalloproteinase-13 (MMP13).","date":"2019","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/30695018","citation_count":29,"is_preprint":false},{"pmid":"29659923","id":"PMC_29659923","title":"A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma.","date":"2018","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/29659923","citation_count":29,"is_preprint":false},{"pmid":"29710483","id":"PMC_29710483","title":"DNMT1/miR-200a/GOLM1 signaling pathway regulates lung adenocarcinoma cells proliferation.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/29710483","citation_count":28,"is_preprint":false},{"pmid":"35443161","id":"PMC_35443161","title":"Cholesterol suppresses GOLM1-dependent selective autophagy of RTKs in hepatocellular carcinoma.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35443161","citation_count":28,"is_preprint":false},{"pmid":"31591387","id":"PMC_31591387","title":"c-Myc transactivates GP73 and promotes metastasis of hepatocellular carcinoma cells through GP73-mediated MMP-7 trafficking in a mildly hypoxic microenvironment.","date":"2019","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/31591387","citation_count":28,"is_preprint":false},{"pmid":"29349903","id":"PMC_29349903","title":"GP73 promotes invasion and metastasis of bladder cancer by regulating the epithelial-mesenchymal transition through the TGF-β1/Smad2 signalling pathway.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29349903","citation_count":28,"is_preprint":false},{"pmid":"29226636","id":"PMC_29226636","title":"The Value of GPC3 and GP73 in Clinical Diagnosis of Hepatocellular Carcinoma.","date":"2017","source":"Clinical laboratory","url":"https://pubmed.ncbi.nlm.nih.gov/29226636","citation_count":27,"is_preprint":false},{"pmid":"28880012","id":"PMC_28880012","title":"GOLPH2-regulated oncolytic adenovirus, GD55, exerts strong killing effect on human prostate cancer stem-like cells in vitro and in vivo.","date":"2017","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/28880012","citation_count":26,"is_preprint":false},{"pmid":"30796901","id":"PMC_30796901","title":"Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B.","date":"2019","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30796901","citation_count":24,"is_preprint":false},{"pmid":"15180731","id":"PMC_15180731","title":"GP73 and liver disease: a (Golgi) complex enigma.","date":"2004","source":"The American journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/15180731","citation_count":23,"is_preprint":false},{"pmid":"33294262","id":"PMC_33294262","title":"GOLM1 upregulates expression of PD-L1 through EGFR/STAT3 pathway in hepatocellular carcinoma.","date":"2020","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33294262","citation_count":23,"is_preprint":false},{"pmid":"20184749","id":"PMC_20184749","title":"GOLPH2 expression may serve as diagnostic marker in seminomas.","date":"2010","source":"BMC urology","url":"https://pubmed.ncbi.nlm.nih.gov/20184749","citation_count":23,"is_preprint":false},{"pmid":"24608522","id":"PMC_24608522","title":"GP73 is upregulated by hepatitis C virus (HCV) infection and enhances HCV secretion.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24608522","citation_count":23,"is_preprint":false},{"pmid":"26993603","id":"PMC_26993603","title":"GP73 N-glycosylation at Asn144 reduces hepatocellular carcinoma cell motility and invasiveness.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26993603","citation_count":22,"is_preprint":false},{"pmid":"24560809","id":"PMC_24560809","title":"GP73, a new marker for diagnosing HBV-ACLF in population with chronic HBV infections.","date":"2014","source":"Diagnostic microbiology and infectious disease","url":"https://pubmed.ncbi.nlm.nih.gov/24560809","citation_count":22,"is_preprint":false},{"pmid":"30405775","id":"PMC_30405775","title":"MicroRNA-143 regulates cell migration and invasion by targeting GOLM1 in cervical cancer.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/30405775","citation_count":21,"is_preprint":false},{"pmid":"32850310","id":"PMC_32850310","title":"Circular RNA 103862 Promotes Proliferation and Invasion of Laryngeal Squamous Cell Carcinoma Cells Through the miR-493-5p/GOLM1 Axis.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32850310","citation_count":21,"is_preprint":false},{"pmid":"33649292","id":"PMC_33649292","title":"The functional landscape of Golgi membrane protein 1 (GOLM1) phosphoproteome reveal GOLM1 regulating P53 that promotes malignancy.","date":"2021","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/33649292","citation_count":20,"is_preprint":false},{"pmid":"28075476","id":"PMC_28075476","title":"Silencing of GP73 inhibits invasion and metastasis via suppression of epithelial-mesenchymal transition in hepatocellular carcinoma.","date":"2017","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/28075476","citation_count":20,"is_preprint":false},{"pmid":"34650031","id":"PMC_34650031","title":"GP73-mediated secretion of AFP and GP73 promotes proliferation and metastasis of hepatocellular carcinoma cells.","date":"2021","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/34650031","citation_count":19,"is_preprint":false},{"pmid":"29344288","id":"PMC_29344288","title":"GP73 level determines chemotherapeutic resistance in human hepatocellular carcinoma cells.","date":"2018","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29344288","citation_count":19,"is_preprint":false},{"pmid":"30034935","id":"PMC_30034935","title":"Down-expression of GOLM1 enhances the chemo-sensitivity of cervical cancer to methotrexate through modulation of the MMP13/EMT axis.","date":"2018","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30034935","citation_count":18,"is_preprint":false},{"pmid":"32077512","id":"PMC_32077512","title":"GP73 facilitates hepatitis B virus replication by repressing the NF-κB signaling pathway.","date":"2020","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/32077512","citation_count":18,"is_preprint":false},{"pmid":"33869063","id":"PMC_33869063","title":"LINC01977 Promotes Breast Cancer Progression and Chemoresistance to Doxorubicin by Targeting miR-212-3p/GOLM1 Axis.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33869063","citation_count":18,"is_preprint":false},{"pmid":"26342810","id":"PMC_26342810","title":"Multiple lectin assays for detecting glyco-alteration of serum GP73 in liver diseases.","date":"2015","source":"Glycoconjugate journal","url":"https://pubmed.ncbi.nlm.nih.gov/26342810","citation_count":17,"is_preprint":false},{"pmid":"33822440","id":"PMC_33822440","title":"STAT3 activates the transcription of lncRNA NR2F1-AS1 to promote the progression of melanoma via regulating the miR-493-5p/GOLM1 axis.","date":"2021","source":"The journal of gene medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33822440","citation_count":17,"is_preprint":false},{"pmid":"22542941","id":"PMC_22542941","title":"Cloning and characterization of human Golgi phosphoprotein 2 gene (GOLPH2/GP73/GOLM1) promoter.","date":"2012","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/22542941","citation_count":16,"is_preprint":false},{"pmid":"26461057","id":"PMC_26461057","title":"Golgi phosphoprotein 2 (GOLPH2) is a novel bile acid-responsive modulator of oesophageal cell migration and invasion.","date":"2015","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26461057","citation_count":16,"is_preprint":false},{"pmid":"34007135","id":"PMC_34007135","title":"Long non-coding RNA TP73-AS1 promotes pancreatic cancer growth and metastasis through miRNA-128-3p/GOLM1 axis.","date":"2021","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/34007135","citation_count":16,"is_preprint":false},{"pmid":"25530841","id":"PMC_25530841","title":"Epithelium-Specific ETS (ESE)-1 upregulated GP73 expression in hepatocellular carcinoma cells.","date":"2014","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/25530841","citation_count":16,"is_preprint":false},{"pmid":"21694465","id":"PMC_21694465","title":"Analysis of GP73 in patients with HCC as a function of anti-cancer treatment.","date":"2010","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/21694465","citation_count":16,"is_preprint":false},{"pmid":"34536514","id":"PMC_34536514","title":"Suppression of GOLM1 by EGCG through HGF/HGFR/AKT/GSK-3β/β-catenin/c-Myc signaling pathway inhibits cell migration of MDA-MB-231.","date":"2021","source":"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association","url":"https://pubmed.ncbi.nlm.nih.gov/34536514","citation_count":15,"is_preprint":false},{"pmid":"34729117","id":"PMC_34729117","title":"GOLM1 Drives Colorectal Cancer Metastasis by Regulating Myeloid-derived Suppressor Cells.","date":"2021","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34729117","citation_count":15,"is_preprint":false},{"pmid":"30935831","id":"PMC_30935831","title":"GOLM1 silencing inhibits the proliferation and motility of human glioblastoma cells via the Wnt/β-catenin signaling pathway.","date":"2019","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/30935831","citation_count":15,"is_preprint":false},{"pmid":"34772312","id":"PMC_34772312","title":"Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis.","date":"2021","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/34772312","citation_count":14,"is_preprint":false},{"pmid":"26125916","id":"PMC_26125916","title":"Sublingual vein parameters, AFP, AFP-L3, and GP73 in patients with hepatocellular carcinoma.","date":"2015","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/26125916","citation_count":14,"is_preprint":false},{"pmid":"24351813","id":"PMC_24351813","title":"CXCL10 decreases GP73 expression in hepatoma cells at the early stage of hepatitis C virus (HCV) infection.","date":"2013","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24351813","citation_count":14,"is_preprint":false},{"pmid":"30396165","id":"PMC_30396165","title":"GOLM1 Stimulation of Glutamine Metabolism Promotes Osteoporosis via Inhibiting Osteogenic Differentiation of BMSCs.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30396165","citation_count":13,"is_preprint":false},{"pmid":"30615900","id":"PMC_30615900","title":"GP73, a novel TGF-β target gene, provides selective regulation on Smad and non-Smad signaling pathways.","date":"2019","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/30615900","citation_count":13,"is_preprint":false},{"pmid":"28943903","id":"PMC_28943903","title":"High expression of GP73 in primary hepatocellular carcinoma and its function in the assessment of transcatheter arterial chemoembolization.","date":"2017","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/28943903","citation_count":13,"is_preprint":false},{"pmid":"25170213","id":"PMC_25170213","title":"Effect of GP73 silencing on proliferation and apoptosis in hepatocellular cancer.","date":"2014","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/25170213","citation_count":13,"is_preprint":false},{"pmid":"23554786","id":"PMC_23554786","title":"Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA.","date":"2012","source":"Journal of biomedical research","url":"https://pubmed.ncbi.nlm.nih.gov/23554786","citation_count":13,"is_preprint":false},{"pmid":"30217697","id":"PMC_30217697","title":"Overexpression of GP73 promotes cell invasion, migration and metastasis by inducing epithelial-mesenchymal transition in pancreatic cancer.","date":"2018","source":"Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/30217697","citation_count":13,"is_preprint":false},{"pmid":"23742050","id":"PMC_23742050","title":"GP73 is down-regulated in gastric cancer and associated with tumor differentiation.","date":"2013","source":"World journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23742050","citation_count":13,"is_preprint":false},{"pmid":"24068434","id":"PMC_24068434","title":"GP73 is a potential marker for evaluating AIDS progression and antiretroviral therapy efficacy.","date":"2013","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24068434","citation_count":13,"is_preprint":false},{"pmid":"20570408","id":"PMC_20570408","title":"Genetic variation in GOLM1 and prefrontal cortical volume in Alzheimer's disease.","date":"2010","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/20570408","citation_count":13,"is_preprint":false},{"pmid":"35948172","id":"PMC_35948172","title":"GOLM1 depletion modifies cellular sphingolipid metabolism and adversely affects cell growth.","date":"2022","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/35948172","citation_count":12,"is_preprint":false},{"pmid":"28880107","id":"PMC_28880107","title":"Association of GOLPH2 expression with survival in non-small-cell lung cancer: clinical implications and biological validation.","date":"2017","source":"Biomarkers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28880107","citation_count":12,"is_preprint":false},{"pmid":"32171652","id":"PMC_32171652","title":"Dynamic expression of hepatic GP73 mRNA and protein and circulating GP73 during hepatocytes malignant transformation.","date":"2020","source":"Hepatobiliary & pancreatic diseases international : HBPD INT","url":"https://pubmed.ncbi.nlm.nih.gov/32171652","citation_count":12,"is_preprint":false},{"pmid":"30425529","id":"PMC_30425529","title":"Research progress on GP73 in malignant tumors.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30425529","citation_count":12,"is_preprint":false},{"pmid":"22719994","id":"PMC_22719994","title":"Xenopus as a model system for the study of GOLPH2/GP73 function: Xenopus GOLPH2 is required for pronephros development.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22719994","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50862,"output_tokens":9017,"usd":0.143921,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19017,"output_tokens":6352,"usd":0.126943,"stage2_stop_reason":"end_turn"},"total_usd":0.270864,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"GP73/GOLM1 is an integral membrane protein localized to the Golgi apparatus, as determined by in vitro transcription-translation studies and immunolocalization experiments using epitope-tagged GP73; it is preferentially expressed by epithelial cells and is normally absent from hepatocytes but upregulated in response to viral infection.\",\n      \"method\": \"In vitro transcription-translation, epitope-tag immunolocalization, Northern blot, immunohistochemistry\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (in vitro translation, epitope-tag localization, IHC) in the foundational characterization paper, replicated in subsequent studies\",\n      \"pmids\": [\"10831838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"GP73 expression is upregulated at the RNA and protein level by adenovirus infection, and this induction requires the CtBP interaction domain (CID) of the adenoviral E1A protein, as demonstrated by infection with a panel of E1A mutant adenoviruses and transient transfection of wild-type vs. mutant E1A constructs.\",\n      \"method\": \"RNase protection assay, immunoblotting, immunofluorescence, infection with mutant adenoviruses, transient transfection of E1A mutants\",\n      \"journal\": \"Virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (RPA, WB, IF) combined with systematic mutagenesis of E1A in a single rigorous study\",\n      \"pmids\": [\"12359426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Soluble GP73 is released from cells by proprotein convertase (furin)-mediated cleavage of its ectodomain. GP73 traffics from the cis-Golgi to the trans-Golgi network and endosomes, and cleavage occurs at a PC consensus site in the endosomal compartment. Alanine substitutions in the PC consensus site blocked both in vitro and in vivo cleavage, establishing the mechanism of GP73 secretion into serum.\",\n      \"method\": \"In vitro cleavage assay with purified furin, site-directed alanine mutagenesis, cleavage-specific antibody, subcellular fractionation/immunofluorescence of endosomes\",\n      \"journal\": \"Traffic\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic assay with purified furin, mutagenesis of the cleavage site, and in-cell localization studies all in one rigorous study\",\n      \"pmids\": [\"17662025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"At least two of three potential N-linked glycosylation sites on GP73 are occupied; the major glycoforms on secreted GP73 are bi-antennary with core fucose, with a smaller fraction of tri- and tetra-antennary structures, and approximately three-quarters of secreted GP73 is fucosylated, as determined by lectin affinity chromatography and mass spectrometry.\",\n      \"method\": \"Lectin affinity chromatography, mass spectrometry, recombinant GP73 expression\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mass spectrometry plus lectin chromatography in one study; single lab but two orthogonal analytical methods on endogenous and recombinant protein\",\n      \"pmids\": [\"18004786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"C-terminal truncation of GP73 in mice (gene-trap approach generating GP73^tr/tr) causes reduced survival, focal segmental glomerulosclerosis, hyaline thrombi in kidneys, and microvesicular hepatic steatosis with nuclear membrane irregularities, indicating that the GP73 C-terminus is essential for normal epithelial cell function in kidney and liver.\",\n      \"method\": \"Gene trap mouse model, histopathology, immunohistochemistry\",\n      \"journal\": \"International journal of clinical and experimental pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function in vivo model with defined phenotypic readout, single lab\",\n      \"pmids\": [\"18830387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The Golgi localization of GOLPH2/GOLM1 is determined by its transmembrane domain combined with a positively charged residue in the cytoplasmic N-terminal tail; the C-terminal luminal domain is dispensable for Golgi targeting. Additionally, both endogenous and secreted GOLPH2 exist as disulfide-bonded dimers, and the coiled-coil domain is sufficient for dimerization.\",\n      \"method\": \"Truncation mutant panel, immunofluorescence microscopy, non-reducing SDS-PAGE, domain deletion analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — systematic domain-deletion mutagenesis with direct localization readout and biochemical dimerization assay, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"22140547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"GOLPH2/GOLM1 interacts with secretory clusterin (sCLU); the coiled-coil domain of GOLPH2 is sufficient for binding to sCLU, confirmed by yeast two-hybrid screening, intracellular co-immunoprecipitation, and co-localization in the Golgi.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, co-localization by immunofluorescence\",\n      \"journal\": \"Molecular biology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — yeast two-hybrid plus co-IP plus co-localization in single lab; multiple methods but no functional mutagenesis or rescue\",\n      \"pmids\": [\"20842452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"IL-6 and oncostatin M (OSM) upregulate GP73 mRNA and protein in hepatoma (HepG2) cells via the shared receptor subunit gp130 and correlate with increased STAT3 phosphorylation; maximal induction requires new protein synthesis, suggesting indirect transcriptional regulators are involved.\",\n      \"method\": \"Cytokine treatment of HepG2 cells, Western blot, STAT3 phosphorylation analysis, protein synthesis inhibition with cycloheximide\",\n      \"journal\": \"Cancer biomarkers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based mechanistic experiments with signaling pathway readouts and inhibitor controls, single lab\",\n      \"pmids\": [\"23144154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The GOLPH2/GOLM1 promoter (2599 bp fragment) is TATA-less and maintains epithelial specificity. A repressive region (−864 to −734 bp), a positive regulatory region (−734 to −421 bp), and a core promoter region (−421 to −79 bp) were identified by deletion analysis. Adenoviral E1A activates GOLPH2 via its CtBP interaction domain; a GC-box motif (−89 to −83 bp) in the core promoter partly mediates E1A transactivation.\",\n      \"method\": \"Promoter cloning, deletion analysis, luciferase reporter assay, E1A transient transfection\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic promoter deletion plus reporter assay plus E1A mutant analysis, single lab\",\n      \"pmids\": [\"22542941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Epithelium-specific ETS transcription factor ESE-1 directly binds the GP73 promoter and activates GP73 transcription. Both ESE-1 and GP73 are co-induced by IL-1β in hepatocellular carcinoma cells and during liver inflammation in vivo; knockdown of ESE-1 reduces GP73 expression.\",\n      \"method\": \"Promoter reporter assay, ChIP (direct binding to GP73 promoter), siRNA knockdown, overexpression, in vivo liver inflammation model\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating direct transcription factor binding, supported by gain- and loss-of-function experiments, single lab\",\n      \"pmids\": [\"25530841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GP73 enhances HCV secretion through its coiled-coil domain and by interacting with apolipoprotein E (ApoE), a host factor required for HCV secretion; GP73 overexpression or knockdown had no effect on HCV entry, protein translation, RNA replication, or assembly, placing GP73 specifically in the secretion step.\",\n      \"method\": \"Co-immunoprecipitation (GP73-ApoE interaction), GP73 overexpression/knockdown in HCV replicon and infected cell systems, domain deletion (coiled-coil mutant)\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain-mapping combined with Co-IP and systematic step-by-step HCV lifecycle assays, single lab\",\n      \"pmids\": [\"24608522\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"mTORC1 positively regulates GP73 expression in HCC and other cancer cell lines; rapamycin (mTORC1 inhibitor) reduces GP73 levels in cancer cell lines and in xenograft tumors. GP73 overexpression promotes HCC cell proliferation and migration in vitro and accelerates xenograft tumor growth and metastasis in mice; GP73 knockout mice show reduced liver damage after diethylnitrosamine administration.\",\n      \"method\": \"Retroviral GP73 overexpression, shRNA knockdown, GP73 knockout mice, xenograft mouse models, rapamycin treatment, microarray gene expression, PTEN-null MEFs with constitutively active mTOR\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal approaches (KO mice, KD, OE, pharmacological inhibition, xenograft) in a single comprehensive study\",\n      \"pmids\": [\"25980751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GOLM1 selectively interacts with EGFR and other RTKs and functions as a cargo adaptor to anchor EGFR/RTKs on the trans-Golgi network (TGN) and recycle them back to the plasma membrane, leading to prolonged downstream kinase activation and promoting HCC metastasis.\",\n      \"method\": \"Co-immunoprecipitation (GOLM1-EGFR interaction), gain- and loss-of-function studies, RTK recycling assays, gene expression profiling of HCC tissues\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, gain- and loss-of-function with defined molecular mechanism, replicated in multiple cell lines and in vivo\",\n      \"pmids\": [\"27569582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"N-glycosylation of GP73 at Asn144 reduces hepatocellular carcinoma cell motility and invasiveness; removal of N-glycans at Asn144 by site-directed mutagenesis enhances cell migration and invasion, possibly by altering cell membrane glycosylation and cell adhesion. Three N-glycosylation sites were identified (Asn109, Asn144, Asn398) by mass spectrometry, with five glycoforms at Asn144.\",\n      \"method\": \"Mass spectrometry for glycosylation site mapping, lectin microarray, site-directed mutagenesis of Asn144, cell migration and invasion assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — site-directed mutagenesis combined with mass spectrometry and functional cell-based assays, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"26993603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GP73 acts as a negative regulator of innate immunity to facilitate HCV infection: upon HCV infection, MAVS recruits TRAF6 via TRAF-interacting motifs; TRAF6 then directly recruits GP73 to MAVS via GP73's coiled-coil domain. GP73 then promotes proteasome-dependent degradation of both MAVS and TRAF6, attenuating IFN-β and NF-κB signaling.\",\n      \"method\": \"Co-immunoprecipitation (GP73-MAVS, GP73-TRAF6), domain mapping (coiled-coil deletion), proteasome inhibitor experiments, IFN-β/NF-κB reporter assays, GP73 knockdown in primary human hepatocytes and Huh7 cells, rescue with shRNA-resistant GP73 mutant\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, domain mapping, proteasome inhibition, knockdown+rescue in primary cells; multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"28394926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GOLM1 promotes prostate cancer progression by activating the PI3K-AKT-mTOR signaling pathway; PI3K inhibitor BKM120 abrogates GOLM1's oncogenic effects on proliferation, migration, invasion, and apoptosis in PCa cell lines and xenograft models.\",\n      \"method\": \"GOLM1 overexpression and knockdown in PCa cell lines, xenograft mouse models, PI3K inhibitor treatment, Western blot for AKT/mTOR pathway components\",\n      \"journal\": \"The Prostate\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with pathway inhibitor rescue, in vitro and in vivo, single lab\",\n      \"pmids\": [\"29181846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PDGFA/PDGFRα signaling regulates GOLM1 expression; GOLM1 in turn promotes glioma progression through activation of AKT. GOLM1 is a key element in the PDGFA/PDGFRα-mediated AKT activation cascade, as demonstrated by PDGFRα inhibitor AG1296 and AKT inhibitor MK-2206 experiments.\",\n      \"method\": \"siRNA knockdown and lentiviral overexpression of GOLM1 in glioma cells, PDGFRα inhibitor (AG1296), AKT inhibitor (MK-2206), membrane-based kinase antibody array, orthotopic implantation in vivo\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic gain/loss-of-function, pathway inhibitor experiments, in vivo validation, single lab\",\n      \"pmids\": [\"29282077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"c-Myc transcriptionally activates GP73 in a mildly hypoxic microenvironment; GP73 then interacts with intracellular MMP-7 via its cytoplasmic domain and facilitates MMP-7 trafficking and secretion, promoting HCC cell metastasis.\",\n      \"method\": \"ChIP assay (c-Myc binding to GP73 promoter), co-immunoprecipitation (GP73-MMP-7), cytoplasmic domain interaction mapping, MMP-7 secretion assays, cell invasion assays\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for transcriptional regulation and Co-IP for direct protein interaction, single lab\",\n      \"pmids\": [\"31591387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"mTOR negatively regulates miR-145 expression; miR-145 directly inhibits GOLM1 by targeting its coding sequence. GOLM1-enriched exosomes activate the GSK-3β/MMP signaling axis in recipient cells, accelerating proliferation and migration.\",\n      \"method\": \"miR-145 target validation (luciferase reporter assay targeting CDS of GOLM1), exosome isolation and transfer assay, GSK-3β/MMP pathway analysis, in vivo mouse HCC model\",\n      \"journal\": \"Journal of genetics and genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase reporter validation plus exosome functional transfer assay plus in vivo, single lab\",\n      \"pmids\": [\"31186161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GP73 is a direct transcriptional target of TGF-β1; upregulated GP73 inhibits TGF-β-Smad-mediated growth suppression while enhancing ERK/AKT signaling downstream of TGF-β1. Mechanistically, GP73 upregulates lipid rafts/caveolin-1, which mediates the switch from Smad to non-Smad TGF-β1 signaling.\",\n      \"method\": \"TGF-β1 reporter assay, GP73 overexpression/knockdown, Western blot for Smad and ERK/AKT phosphorylation, lipid raft isolation, caveolin-1 staining\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic signaling experiments with lipid raft biochemistry and gain/loss-of-function, single lab\",\n      \"pmids\": [\"30615900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GOLM1 upregulates PD-L1 expression via the EGFR/STAT3 signaling pathway in HCC cells: GOLM1 enhances EGFR levels, which promotes STAT3 phosphorylation, which in turn increases PD-L1 transcription.\",\n      \"method\": \"GOLM1 overexpression/knockdown, Western blot for EGFR and p-STAT3, STAT3 inhibitor treatment, PD-L1 expression analysis\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with pharmacological pathway inhibition, single lab\",\n      \"pmids\": [\"33294262\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GOLM1 promotes COP9 signalosome 5-mediated PD-L1 deubiquitination in HCC cells, stabilizing PD-L1, and suppresses Rab27b expression to increase transport of PD-L1 into exosomes. Exosomes containing PD-L1 from GOLM1-high HCC cells upregulate PD-L1 on macrophages, inducing CD8+ T cell suppression.\",\n      \"method\": \"Gain- and loss-of-function studies, co-culture assays with exosomes, Rab27b expression analysis, ubiquitination/deubiquitination assays, flow cytometry for CD8+ T cells\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway studies with exosome transfer assay and in vivo mouse model, single lab\",\n      \"pmids\": [\"34795203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GOLM1 depletion in intestinal epithelial cells leads to aberrant Notch pathway activation, interfering with IEC differentiation, maturation, and lineage commitment. GOLM1-deficient mice are susceptible to mucosal inflammation and colitis-induced epithelial damage; pharmacological inhibition of Notch alleviates epithelial lesions in GOLM1-deficient mice, placing GOLM1 upstream of Notch equilibrium.\",\n      \"method\": \"GOLM1 knockout mice (colitis models), Notch pathway inhibition (gamma-secretase inhibitor), histopathology, marker gene expression analysis\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis via pharmacological rescue in KO mice, single lab\",\n      \"pmids\": [\"33850109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GP73 is a Rab GTPase-activating protein (RabGAP) with TBC domain activity that regulates ApoB export from hepatocytes; liver-specific GP73-overexpressing mice develop non-obese NAFLD (intrahepatic lipid accumulation, insulin resistance, reduced body weight), a phenotype not recapitulated by a GAP-inactive GP73 mutant. Metformin inactivates the GAP activity of GP73 and alleviates this non-obese NAFLD phenotype.\",\n      \"method\": \"RabGAP activity assay, TBC-domain mutagenesis (GAP-inactive mutant), liver-specific GP73 transgenic mice, high-fat diet NAFLD comparison, metformin treatment, ApoB export assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — enzymatic GAP activity assay combined with active-site mutagenesis, transgenic mouse model, pharmacological rescue with metformin, multiple orthogonal methods in one study\",\n      \"pmids\": [\"34853313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GOLM1 promotes liver fibrosis-induced PD-L1 upregulation and immune escape in HCC via the EGFR signaling pathway; GOLM1 levels are increased in fibrotic livers and hepatocyte-specific GOLM1 transgenic mice show decreased CD8+ T cell infiltration and increased PD-L1 in tumors during chemical carcinogenesis. EGFR inhibitors improve immunotherapy efficacy.\",\n      \"method\": \"Hepatocyte-specific GOLM1 transgenic mice, CCl4-induced fibrosis model, EGFR inhibitor treatment, immunohistochemistry for CD8+ T cells and PD-L1, EGFR pathway Western blot\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic mouse gain-of-function combined with pharmacological inhibitor rescue, single lab\",\n      \"pmids\": [\"33992711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GP73 directly binds AFP and increases AFP secretion from HCC cells; extracellular GP73 independently promotes HCC cell proliferation and metastasis, and extracellular GP73 and AFP synergize to enhance HCC malignancy and drug resistance to sorafenib.\",\n      \"method\": \"Co-immunoprecipitation (GP73-AFP direct binding), GP73 overexpression/knockdown, AFP secretion assays, cell proliferation and metastasis assays, sorafenib resistance assay\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding demonstrated by Co-IP, functional secretion assay, single lab\",\n      \"pmids\": [\"34650031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GOLM1 overexpression enhances phosphorylation of p53 at Ser315 and inhibits p53 tetramer formation, reducing p53 tumor-suppressor function; this effect is associated with GOLM1-driven lung cancer aggressiveness as shown by phosphoproteomic analysis.\",\n      \"method\": \"Phosphoproteomics (phosphoprotein array), Western blot for p53 phospho-Ser315, p53 tetramer native gel assay, GOLM1 overexpression/knockdown, xenograft in vivo\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphoproteomics combined with biochemical p53 tetramer assay, single lab\",\n      \"pmids\": [\"33649292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cholesterol suppresses GOLM1-dependent autophagic degradation of RTKs: GOLM1 mediates selective autophagy of RTKs by interacting with LC3 through an LC3-interacting region (LIR) motif, and this interaction is regulated by a cholesterol-mTORC1 axis. High cholesterol activates mTORC1 to suppress the LIR-LC3 interaction, switching GOLM1 from promoting RTK degradation to promoting RTK recycling.\",\n      \"method\": \"Co-immunoprecipitation (GOLM1-LC3), LIR motif mutagenesis, autophagic flux assays, cholesterol manipulation, mTORC1 inhibition, statin treatment in vivo with RTK inhibitors\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mutagenesis of LIR motif combined with Co-IP, autophagic flux assays, pharmacological manipulation of cholesterol and mTORC1, and in vivo combination therapy experiments\",\n      \"pmids\": [\"35443161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GP73 functions as a glucogenic hormone: fasting induces GP73 secretion from multiple tissues; secreted GP73 stimulates hepatic gluconeogenesis through the cAMP/PKA signaling pathway. SARS-CoV-2 infection increases GP73 secretion, and GP73 antibody blockade inhibits excessive gluconeogenesis in SARS-CoV-2-infected mice and lowers fasting blood glucose.\",\n      \"method\": \"GP73 recombinant protein treatment of hepatocytes, cAMP/PKA pathway inhibitors, GP73-neutralizing antibody in mice, mouse-adapted SARS-CoV-2 infection model, fasting experiments in multiple tissues\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct recombinant protein activity assay demonstrating gluconeogenic effect, signaling pathway identification, in vivo antibody neutralization with multiple disease models\",\n      \"pmids\": [\"34992299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ASGR1 (asialoglycoprotein receptor 1) directly binds GP73 and facilitates its lysosomal degradation; ASGR1 deficiency increases circulating GP73 levels. Elevated GP73 then interacts with BIP/GRP78 to activate endoplasmic reticulum stress, causing liver injury. GP73 neutralization attenuates ASGR1-deficiency-induced liver injuries.\",\n      \"method\": \"Co-immunoprecipitation (ASGR1-GP73, GP73-BIP), lysosomal degradation assays, ASGR1 knockout and overexpression in mice, GP73-neutralizing antibody rescue experiments, acetaminophen and CCl4 liver injury models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — reciprocal Co-IP demonstrating direct binding to two partners, genetic KO and OE with antibody rescue, multiple in vivo injury models\",\n      \"pmids\": [\"38459023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GP73 promotes HCC tumor angiogenesis by directly binding STAT3 and simultaneously enhancing GRP78-induced endoplasmic reticulum stress; GP73 is activated transcriptionally by histone lactylation and c-Myc, and GP73-mediated STAT3 phosphorylation potentiates pro-angiogenic functions.\",\n      \"method\": \"Co-immunoprecipitation (GP73-STAT3), ChIP for c-Myc and histone lactylation at GP73 locus, in vitro and in vivo angiogenesis assays, single-cell and spatial transcriptomics\",\n      \"journal\": \"Research (Washington, D.C.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for direct binding, ChIP for transcriptional regulation, in vitro and in vivo functional assays, single lab\",\n      \"pmids\": [\"38939041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"In Xenopus, morpholino-mediated knockdown of golph2/GOLM1 causes edema, enhanced Nephrin expression in the glomus, reduced expression of pronephric tubule/duct markers (atp1b1, ClC-K, NKCC2, NBC1), and expanded WT1 expression, demonstrating that GOLPH2 is required for normal pronephros development by modulating WT1-dependent differentiation of the pronephric field.\",\n      \"method\": \"Morpholino knockdown in Xenopus embryos, in situ hybridization for pronephric marker genes, immunostaining for WT1\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — morpholino loss-of-function in a vertebrate model organism with multiple defined marker readouts, single lab; Xenopus golph2 protein confirmed to dimerize and localize to Golgi like human GOLPH2\",\n      \"pmids\": [\"22719994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GOLM1 depletion in Huh-7 HCC cells causes aberrant accumulation of ceramides, hexosylceramides, dihexosylceramides, sphinganine, sphingosine, ceramide phosphate, and cholesteryl esters, with reduction in phosphatidylethanolamines, demonstrating that GOLM1 is required for normal cellular sphingolipid homeostasis. GOLM1 depletion also disrupts Golgi structure and reduces mitochondrial oxygen consumption, and impairs cell proliferation.\",\n      \"method\": \"siRNA-mediated GOLM1 knockdown, mass spectrometric lipidomics, Seahorse extracellular flux analysis, electron microscopy, immunofluorescence for Golgi structure, cell cycle analysis\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (lipidomics, EM, Seahorse) in single lab KD study\",\n      \"pmids\": [\"35948172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GP73 promotes epithelial-mesenchymal transition (EMT) and invasion in HCC partly by activating the TGF-β1/Smad2 signaling pathway; GP73 enhances p-Smad2 and p-Smad3 levels by mediating TGF-β1. Blocking the TGF-β1/Smad pathway with SB431542 partially reverses GP73-driven EMT, but GP73 retains some pro-EMT activity through additional pathways.\",\n      \"method\": \"GP73 overexpression/knockdown in HCC cell lines, Western blot for p-Smad2/3, TGF-β1/Smad pathway inhibitor (SB431542), in vitro invasion assay, in vivo metastasis model\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway rescue combined with gain/loss-of-function, single lab\",\n      \"pmids\": [\"29365054\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GOLM1/GP73 is a type II Golgi transmembrane glycoprotein that (1) is cleaved by furin-family proprotein convertases in the endosomal compartment to generate a secreted ectodomain; (2) acts as a cargo adaptor on the trans-Golgi network to recycle EGFR/RTKs to the plasma membrane, prolonging downstream signaling, and also mediates selective LC3-dependent autophagic degradation of RTKs in a cholesterol- and mTORC1-regulated manner; (3) possesses TBC-domain Rab-GAP activity that controls ApoB export and drives non-obese NAFLD; (4) functions as a circulating glucogenic hormone that stimulates hepatic gluconeogenesis via cAMP/PKA signaling; (5) interacts with MAVS/TRAF6 to promote their proteasomal degradation and suppress innate immune signaling; (6) regulates PD-L1 stability and exosomal transport to promote immune escape via EGFR/STAT3; (7) modulates sphingolipid homeostasis through its role in Golgi structure and trafficking; and (8) is transcriptionally regulated by c-Myc, ESE-1, TGF-β1, IL-6/OSM via STAT3, and the adenoviral E1A CtBP-interaction domain.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GOLM1 (GP73/GOLPH2) is a type II Golgi transmembrane glycoprotein that couples Golgi trafficking control to receptor signaling, secretion, and systemic metabolism, and is repeatedly co-opted to drive hepatocellular carcinoma and other cancers [#0, #12, #11]. Its Golgi residence is specified by the transmembrane domain plus a positively charged cytoplasmic residue, and the coiled-coil domain mediates disulfide-bonded dimerization and most protein-protein interactions [#5]. GOLM1 traffics from the cis-Golgi to the trans-Golgi network and endosomes, where furin-family proprotein convertases cleave a luminal consensus site to release a heavily fucosylated, N-glycosylated soluble ectodomain into serum [#2, #3]. At the TGN, GOLM1 acts as a cargo adaptor that binds EGFR and other receptor tyrosine kinases to recycle them to the plasma membrane and prolong downstream kinase signaling, thereby promoting metastasis [#12]; a cholesterol-mTORC1 axis toggles this activity, since GOLM1 also engages LC3 through an LIR motif to route RTKs into selective autophagic degradation when cholesterol and mTORC1 are low [#27]. GOLM1 possesses TBC-domain Rab-GAP activity that controls hepatic ApoB export, and liver-specific overexpression drives non-obese NAFLD in a manner abolished by a GAP-inactive mutant and reversed by metformin [#23]. The secreted ectodomain functions as a fasting-induced glucogenic hormone that stimulates hepatic gluconeogenesis via cAMP/PKA signaling [#28]. GOLM1 additionally suppresses innate immunity by being recruited to MAVS via TRAF6 to drive proteasomal degradation of both, dampening IFN-\\u03b2 and NF-\\u03baB signaling [#14], and promotes immune escape by stabilizing and exosomally exporting PD-L1 through EGFR/STAT3 [#20, #21]. Across cancers GOLM1 is transcriptionally induced by c-Myc, ESE-1, TGF-\\u03b21, and IL-6/OSM-STAT3 signaling, and these inputs feed forward into PI3K-AKT-mTOR, EGFR, and STAT3 signaling axes [#9, #7, #19, #15, #12].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established the molecular identity and disease context of GP73: an integral Golgi membrane protein normally restricted from hepatocytes but induced by viral infection, framing it as a liver-disease-associated Golgi protein.\",\n      \"evidence\": \"In vitro transcription-translation, epitope-tag immunolocalization, Northern blot and IHC across epithelial tissues\",\n      \"pmids\": [\"10831838\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No molecular function assigned\", \"Mechanism of viral induction undefined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined how viral infection induces GP73, showing the adenoviral E1A CtBP-interaction domain is required, linking GP73 expression to a specific transcriptional co-repressor pathway.\",\n      \"evidence\": \"RNase protection, immunoblot/IF, and infection with E1A mutant adenoviruses plus transient E1A transfection\",\n      \"pmids\": [\"12359426\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not map the cellular transcription factors recruited via CID\", \"No endogenous viral context beyond adenovirus\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Resolved the mechanism by which GP73 becomes a serum protein: furin-mediated cleavage at a PC consensus site in the endosomal compartment liberates the ectodomain, explaining its biomarker behavior.\",\n      \"evidence\": \"In vitro cleavage assay with purified furin, alanine mutagenesis of the cleavage site, cleavage-specific antibody and endosomal fractionation/IF\",\n      \"pmids\": [\"17662025\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Function of the secreted ectodomain not yet known\", \"Regulation of cleavage rate unaddressed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Characterized GP73 glycosylation (predominantly core-fucosylated bi-antennary structures) and showed the C-terminus is essential in vivo, with truncation causing kidney and liver pathology.\",\n      \"evidence\": \"Lectin chromatography/MS on recombinant and secreted GP73; gene-trap GP73^tr/tr mouse histopathology\",\n      \"pmids\": [\"18004786\", \"18830387\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of fucosylation undefined\", \"Mechanism linking C-terminus to epithelial pathology unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined the structural determinants of GP73 — TM-plus-charged-residue Golgi targeting and coiled-coil-mediated dimerization — and identified secretory clusterin as an early binding partner.\",\n      \"evidence\": \"Truncation/domain-deletion mutants with IF localization and non-reducing SDS-PAGE; yeast two-hybrid, co-IP and co-localization for sCLU\",\n      \"pmids\": [\"22140547\", \"20842452\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"sCLU interaction lacks functional/rescue validation\", \"Functional role of dimerization untested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Connected GP73 expression to inflammatory cytokine signaling and defined core promoter architecture, showing IL-6/OSM-gp130-STAT3 induction and E1A/GC-box-mediated transactivation.\",\n      \"evidence\": \"Cytokine treatment of HepG2 with cycloheximide controls; promoter deletion/luciferase reporter assays with E1A mutants; Xenopus golph2 morpholino developmental study\",\n      \"pmids\": [\"23144154\", \"22542941\", \"22719994\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct STAT3 binding to promoter not demonstrated\", \"Vertebrate pronephros role mechanistically tied only to WT1 marker shifts\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified direct transcription factors (ESE-1) and established a secretion-promoting role in HCV egress via the coiled-coil domain and ApoE interaction.\",\n      \"evidence\": \"ChIP and gain/loss-of-function for ESE-1; co-IP for GP73-ApoE plus stepwise HCV lifecycle assays with coiled-coil deletion\",\n      \"pmids\": [\"25530841\", \"24608522\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether GP73 acts as a general secretion adaptor beyond HCV unaddressed\", \"Single-lab ChIP for ESE-1\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Placed GOLM1 in a feed-forward oncogenic loop with mTORC1 and demonstrated causal tumor-promoting roles in HCC using KO, KD, OE, and xenograft models.\",\n      \"evidence\": \"GP73 KO mice, shRNA, retroviral OE, rapamycin treatment, xenografts and DEN-induced liver damage\",\n      \"pmids\": [\"25980751\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular effector of pro-tumor activity not yet defined at this stage\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined GOLM1's signature molecular activity: a TGN cargo adaptor that binds EGFR/RTKs to recycle them to the plasma membrane and prolong kinase signaling; also linked Asn144 glycosylation to motility control.\",\n      \"evidence\": \"Reciprocal co-IP, RTK recycling assays, gain/loss-of-function in vivo; MS glycosite mapping with Asn144 mutagenesis and migration/invasion assays\",\n      \"pmids\": [\"27569582\", \"26993603\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How adaptor selectivity for RTKs is determined unclear\", \"Glycosylation effect on adhesion partners not identified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Extended GOLM1 oncogenic signaling to PI3K-AKT-mTOR and PDGFA/PDGFR\\u03b1-AKT cascades in prostate cancer and glioma, and identified MMP-7 trafficking under c-Myc/hypoxia control.\",\n      \"evidence\": \"Gain/loss-of-function with PI3K (BKM120), PDGFR\\u03b1 (AG1296) and AKT (MK-2206) inhibitors, kinase arrays, xenograft/orthotopic models; ChIP for c-Myc and co-IP for GP73-MMP-7\",\n      \"pmids\": [\"29181846\", \"29282077\", \"31591387\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether AKT activation is direct or via RTK recycling not resolved\", \"Single-lab studies per cancer type\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed an innate-immune-suppressive function: TRAF6-dependent recruitment of GP73 to MAVS drives proteasomal degradation of MAVS and TRAF6, attenuating antiviral signaling.\",\n      \"evidence\": \"Reciprocal co-IP, coiled-coil deletion mapping, proteasome inhibition, IFN-\\u03b2/NF-\\u03baB reporters, knockdown+rescue in primary hepatocytes\",\n      \"pmids\": [\"28394926\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GP73 recruits an E3 ligase or acts directly is undefined\", \"Generality beyond HCV-triggered signaling untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected GOLM1 to TGF-\\u03b21 signaling rewiring and exosomal communication, showing it switches TGF-\\u03b21 from Smad to non-Smad (ERK/AKT) output and exports pro-tumor cargo via exosomes regulated by mTOR/miR-145.\",\n      \"evidence\": \"TGF-\\u03b21 reporter, lipid raft/caveolin-1 biochemistry, Smad/ERK/AKT phospho-blots; miR-145 luciferase CDS targeting and exosome transfer assays in vivo\",\n      \"pmids\": [\"30615900\", \"31186161\", \"29365054\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanism of Smad-to-nonSmad switch beyond lipid raft correlation unclear\", \"Exosomal cargo selectivity undefined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established GOLM1 as a driver of immune escape, upregulating and stabilizing PD-L1 via EGFR/STAT3 and routing PD-L1 into exosomes through CSN5 deubiquitination and Rab27b suppression.\",\n      \"evidence\": \"Gain/loss-of-function with STAT3 inhibition; ubiquitination assays, Rab27b analysis, exosome co-culture and CD8+ T cell flow cytometry; fibrosis transgenic models with EGFR inhibitors\",\n      \"pmids\": [\"33294262\", \"34795203\", \"33992711\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs RTK-recycling-mediated EGFR effect not separated\", \"Most readouts single-lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Assigned GOLM1 an intrinsic enzymatic activity: TBC-domain Rab-GAP function controlling hepatocyte ApoB export and driving non-obese NAFLD, pharmacologically targetable by metformin.\",\n      \"evidence\": \"RabGAP activity assay, GAP-inactive TBC-domain mutant, liver-specific transgenic mice, ApoB export assays, metformin rescue\",\n      \"pmids\": [\"34853313\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific Rab substrate(s) not definitively identified\", \"Link between GAP activity and adaptor/autophagy roles unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated developmental and homeostatic roles of GOLM1 in epithelium, p53 regulation, and AFP secretion, broadening its biology beyond signaling adaptor functions.\",\n      \"evidence\": \"GOLM1 KO mice colitis models with Notch (\\u03b3-secretase) inhibition; phosphoproteomics and p53 tetramer assays; co-IP for GP73-AFP and secretion assays\",\n      \"pmids\": [\"33850109\", \"33649292\", \"34650031\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which GOLM1 restrains Notch undefined\", \"Direct vs indirect control of p53 Ser315 phosphorylation unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Unified the recycling-vs-degradation switch and identified a Golgi/lipid-homeostasis function: GOLM1 binds LC3 via an LIR motif for selective RTK autophagy under cholesterol-mTORC1 control, and is required for sphingolipid balance and Golgi integrity.\",\n      \"evidence\": \"Co-IP, LIR mutagenesis, autophagic flux, cholesterol/mTORC1 manipulation, in vivo statin+RTK inhibitor therapy; lipidomics, EM, Seahorse on GOLM1-depleted Huh-7 cells\",\n      \"pmids\": [\"35443161\", \"35948172\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How lipid homeostasis defects relate to RTK adaptor function unclear\", \"In vivo relevance of sphingolipid changes untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified the secreted ectodomain as a fasting-induced glucogenic hormone acting through hepatic cAMP/PKA, with pathological elevation in SARS-CoV-2 infection.\",\n      \"evidence\": \"Recombinant GP73 hepatocyte assays, cAMP/PKA inhibitors, neutralizing antibody in mouse-adapted SARS-CoV-2 and fasting models\",\n      \"pmids\": [\"34992299\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor for circulating GP73 on hepatocytes not identified\", \"Relationship to RabGAP-driven hepatic phenotype unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined turnover and downstream stress signaling of circulating GP73: ASGR1 binding routes GP73 to lysosomal degradation, while elevated GP73 binds BIP/GRP78 to trigger ER stress and liver injury, and binds STAT3 to drive tumor angiogenesis.\",\n      \"evidence\": \"Reciprocal co-IP (ASGR1-GP73, GP73-BIP, GP73-STAT3), ASGR1 KO/OE mice with neutralizing antibody rescue in liver injury models; ChIP for c-Myc/histone lactylation and angiogenesis assays\",\n      \"pmids\": [\"38459023\", \"38939041\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ER-stress and STAT3 effects are mediated by secreted vs intracellular GP73 not fully resolved\", \"Histone-lactylation regulation single-lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how GOLM1's distinct activities — TGN cargo adaptor, LIR-dependent autophagy receptor, TBC Rab-GAP, and secreted glucogenic hormone — are coordinated within one protein, and which Rab substrate and which hepatocyte receptor underlie its enzymatic and hormonal functions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model integrating TBC domain, coiled-coil, and LIR motif\", \"Rab-GAP substrate unidentified\", \"Receptor mediating circulating GP73 hormone action unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [12, 27]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [23, 14]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [28]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [0, 5, 2]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [2, 28]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [12, 20, 15]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [27]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [14, 21]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [23, 28, 32]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [12, 2, 21]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [11, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"EGFR\", \"MAVS\", \"TRAF6\", \"MAP1LC3\", \"ASGR1\", \"HSPA5\", \"STAT3\", \"APOE\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":8,"faith_total":8,"faith_pct":100.0}}